Advanced Practice Provider Core Curriculum: Hypogonadism (2020)
Member only benefit! Results of a recent survey sent to US based practicing urologists show that there has been an increase in the number of advanced practice providers (APPs) actively providing front-line urologic care. Based on these findings, it was determined that the AUA develop a modular curriculum to be used in advancing the standard of urologic education for APPs. This educational curriculum, developed in partnership with the Cleveland Clinic, is comprised of online videos targeted towards the most common reasons patients seek non-operative urologic care. This module provides APPs with an understanding of the symptomatology and management of low testosterone as well as the controversy surrounding treatment using testosterone replacement therapy.
AUA would like to acknowledge the following individuals from the Cleveland Clinic for their contributions in assembling and editing this case:
- Hadley Wood, MD, FACS
- Dana Longo, APRN, MPH
- Nikki Williams, Project Manager
- Physician Assistants
- Advanced Practice Nurses
After completion of this activity, participants will be able to:
- Describe the physiologic roles of testosterone and the symptoms of low testosterone.
- Identify the health benefits of testosterone replacement therapy (TRT).
- State the controversies and risks of TRT.
- Describe the options for TRT and how patients should be monitored.
Sarah Vij, MD: Nothing to disclose
Hadley Wood, MD: Nothing to disclose
Jim Kovarik, III, PA-C: Urological Association of Physician Assistants: Leadership Position; Kansas Academy of Physician Assistants: Leadership Position; Abbvie: Investment Interest; Allergan: Investment Interest; Johnson & Johnson: Investment Interest; Pfizer: Investment Interest; CVS Caremark: Investment Interest; Becton Dickinson & Co: Investment Interest; Abbvie: Investment Interest; Allergan: Investment Interest; Johnson & Johnson: Investment Interest;; Pfizer: Investment Interest; Pfizer: Investment Interest; CVS Caremark: Investment Interest; Zimmer Holdings Inc.: Investment Interest
Stephen Kraus, MD: Laborie: Course Director and Teaching Faculty; Allergan: Consultant or Advisor; Astellas: Consultant or Advisor; ICube: Consultant or Advisor
AUA Office of Education Staff has nothing to disclose.
METHOD OF PARTICIPATION:
Learners will participate in this online educational activity by taking the pretest, viewing the online module and completing the posttest and evaluation. To claim CME credit for this enduring material, learners must complete the posttest, passing with 80% accuracy and submit the program evaluation.
Estimated time to complete this activity: 0.50 hours
Renew Date: February, 2020
Original Release Date: February, 2017
Expiration Date: February, 2023
The American Urological Association (AUA) is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The American Urological Association designates this enduring material for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AUA is not accredited to offer credit to participants who are not MDs or DOs. However, the AUA will issue documentation of participation that states that the activity was certified for AMA PRA Category 1 Credit™.
EVIDENCE BASED CONTENT:
It is the policy of the AUA to ensure that the content contained in this CME activity is valid, fair, balanced, scientifically rigorous, and free of commercial bias.
AUA DISCLOSURE POLICY:
All persons in a position to control the content of an educational activity (i.e., activity planners, presenters, authors) are required to disclose to the provider any relevant financial relationships with any commercial interest. The AUA must determine if the individual’s relationships may influence the educational content and resolve any conflicts of interest prior to the commencement of the educational activity. The intent of this disclosure is not to prevent individuals with relevant financial relationships from participating, but rather to provide learners information with which they can make their own judgments.
RESOLUTION OF IDENTIFIED CONFLICT OF INTEREST:
All disclosures will be reviewed by the program/course directors or editors for identification of conflicts of interest. Peer reviewers, working with the program directors and/or editors, will document the mechanism(s) for management and resolution of the conflict of interest and final approval of the activity will be documented prior to implementation. Any of the mechanisms below can/will be used to resolve conflict of interest:
- Peer review for valid, evidence-based content of all materials associated with an educational activity by the course/program director, editor, and/or Education Content Review Committee or its subgroup.
- Limit content to evidence with no recommendations
- Introduction of a debate format with an unbiased moderator (point-counterpoint)
- Inclusion of moderated panel discussion
- Publication of a parallel or rebuttal article for an article that is felt to be biased
- Limit equipment representatives to providing logistics and operation support only in procedural demonstrations
- Divestiture of the relationship by faculty
OFF-LABEL OR UNAPPROVED USE OF DRUGS OR DEVICES:
The audience is advised that this continuing medical education activity may contain reference(s) to off-label or unapproved uses of drugs or devices. Please consult the prescribing information for full disclosure of approved uses.
- 0.50 AMA PRA Category 1 Credit™
- 0.50 Non-Physician Participation